Arock, M
Sotlar, K
Akin, C
Broesby-Olsen, S
Hoermann, G
Escribano, L
Kristensen, T K
Kluin-Nelemans, H C
Hermine, O
Dubreuil, P
Sperr, W R
Hartmann, K
Gotlib, J
Cross, N C P
Haferlach, T
Garcia-Montero, A
Orfao, A
Schwaab, J
Triggiani, M
Horny, H-P
Metcalfe, D D
Reiter, A
Valent, P
Article History
Received: 5 November 2014
Revised: 1 January 2015
Accepted: 9 January 2015
First Online: 4 February 2015
Competing interests
: C Akin is a consultant in a Novartis trial. O Hermine and P Dubreuil receive research funding and honorarium from AB Science. NCP Cross receives honoraria and research funding from Novartis. K Hartmann is a consultant in a Novartis trial and received research grants from Novartis. J Gotlib is a consultant in a Novartis trial and receives research funding from Novartis. A Reiter is a consultant in a Novartis trial and receives honoraria and travel support. P Valent receives honoraria and a research grant from Novartis and is Consultant in a Global Novartis trial. The other authors declare no conflict of interest.